利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.026 秒)

    Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
    1.
    发明授权
    Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof 有权

    公开(公告)号：US10738130B2

    公开(公告)日：2020-08-11

    申请号：US15713574

    申请日：2017-09-22

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Lauric Haber ,  Eric Smith ,  Marcus Kelly ,  Jessica R. Kirshner ,  Sandra Coetzee ,  Alison Crawford ,  Thomas Nittoli ,  Yashu Liu

    IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  C07K16/28 ,  C07K16/44 ,  A61K47/68 ,  G01N33/574 ,  A61K39/00

    摘要： Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

    Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof
    2.
    发明申请
    Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof 审中-公开

    公开(公告)号：US20180112001A1

    公开(公告)日：2018-04-26

    申请号：US15713574

    申请日：2017-09-22

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Lauric Haber ,  Eric Smith ,  Marcus Kelly ,  Jessica R. Kirshner ,  Sandra Coetzee ,  Alison Crawford ,  Thomas Nittoli ,  Yashu Liu

    IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K47/68

    摘要： Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

    Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof
    3.
    发明申请
    Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof 审中-公开

    公开(公告)号：US20200317810A1

    公开(公告)日：2020-10-08

    申请号：US16913154

    申请日：2020-06-26

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Lauric Haber ,  Eric Smith ,  Marcus Kelly ,  Jessica R. Kirshner ,  Sandra Coetzee ,  Alison Crawford ,  Thomas Nittoli ,  Yashu Liu

    IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  C07K16/28 ,  C07K16/44 ,  A61K47/68 ,  G01N33/574

    摘要： Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human andMUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof
    4.
    发明申请
    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof 审中-公开

    公开(公告)号：US20190127480A1

    公开(公告)日：2019-05-02

    申请号：US16205917

    申请日：2018-11-30

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jessica R. Kirshner ,  Alison Crawford ,  Gavin Thurston ,  Eric Smith ,  Lauric Harber ,  Drew Dudgeon ,  Ashique Rafique

    IPC分类号： C07K16/30 ,  C07K16/28 ,  A61P35/00

    摘要： The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules That Bind PSMA and CD3, and Uses Thereof
    7.
    发明申请
    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules That Bind PSMA and CD3, and Uses Thereof 有权

    公开(公告)号：US20210403595A1

    公开(公告)日：2021-12-30

    申请号：US17476856

    申请日：2021-09-16

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jessica R. Kirshner ,  Alison Crawford ,  Gavin Thurston ,  Eric Smith ,  Lauric Haber ,  Drew Dudgeon ,  Ashique Rafique

    IPC分类号： C07K16/30 ,  C07K16/28 ,  A61P35/00

    摘要： The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
    8.
    发明授权
    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof 有权

    公开(公告)号：US11155633B2

    公开(公告)日：2021-10-26

    申请号：US16205917

    申请日：2018-11-30

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jessica R. Kirshner ,  Alison Crawford ,  Gavin Thurston ,  Eric Smith ,  Lauric Haber ,  Drew Dudgeon ,  Ashique Rafique

    IPC分类号： A61K39/00 ,  C07K16/30 ,  C07K16/28 ,  A61P35/00

    摘要： The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof
    9.
    发明申请
    Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof 审中-公开
    绑定PSMA和CD3的抗PSMA抗体，双特异性抗原结合分子及其用途

    公开(公告)号：US20170051074A1

    公开(公告)日：2017-02-23

    申请号：US15223434

    申请日：2016-07-29

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Jessica R. Kirshner ,  Alison Crawford ,  Gavin Thurston

    IPC分类号： C07K16/30 ,  C07K16/28

    CPC分类号： C07K16/3069 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

    摘要： The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers.

    摘要翻译： 本发明提供了结合前列腺特异性膜抗原（PSMA）的抗体，与PSMA和CD3结合的双特异性抗体及其使用方法。 根据某些实施方案，本发明的抗体以高亲和力结合人PSMA并结合CD3以诱导人T细胞增殖。 本发明包括结合PSMA和CD3并诱导T细胞介导的杀伤表达PSMA的肿瘤细胞的抗体。 根据某些实施方案，本发明提供包含特异性结合人CD3的第一抗原结合结构域和特异性结合人PSMA的第二抗原结合分子的双特异性抗原结合分子。 在某些实施方案中，本发明的双特异性抗原结合分子能够抑制表达PSMA的前列腺肿瘤的生长。 本发明的抗体和双特异性抗原结合分子可用于治疗其中期望和/或治疗有益的上调或诱导的靶向免疫应答的疾病和病症。 例如，本发明的抗体可用于治疗各种癌症。